Key result
Post-treatment pulmonary hypertension was associated with increased mortality in patients with primary pulmonary artery sarcoma.
Why the study?
What are the clinical characteristics and prognostic factors for mortality in patients with primary pulmonary artery sarcoma?
Cohort (n=20)
No
What are the clinical characteristics and prognostic factors for mortality in patients with primary pulmonary artery sarcoma?
In patients with primary pulmonary artery sarcoma, post-treatment pulmonary hypertension is a significant predictor of poor prognosis and mortality.
Answers are grounded in this paper and cite their sources.
Post-treatment pulmonary hypertension may aid prognostic stratification in primary pulmonary artery sarcoma; leaves open whether targeted intervention improves survival.
Pulmonary artery sarcomas (PAS) are rare malignant neoplasms. Right heart failure due to tumour location is the main cause of death in PAS patients. The hemodynamic influence of PAS may effect prognosis, but this has not been proven. We aimed to identify the clinical characteristics and prognostic factors of PAS in Korea, their association with pulmonary hypertension (PH). PAS patients treated at the Asan Medical Center between 2000 and 2014 were reviewed. We examined demographic characteristics, diagnostic and treatment modalities. Potential prognostic factors were evaluated by univariate and multivariate analysis. Twenty patients were diagnosed with PAS. Ten patients were male, the median age was 54 years (range, 33-75 years). The most common symptom observed was dyspnea (65%). The most common histologic type was spindle cell sarcoma (30%). Ten patients had a presumptive diagnosis of pulmonary embolism (PE) and received anticoagulation therapy. Seventeen patients underwent surgery, but only 5 patients had complete resection. Eleven patients received post-operative treatment (chemotherapy = 3, radiotherapy = 5, chemoradiotherapy = 3). PH was observed in 12 patients before treatment and in 6 patients after treatment. Overall median survival was 24 months. Post-treatment PH was associated with poor prognosis (HR 9.501, 95% CI 1.79-50.32; P = 0.008) while chemotherapy was negatively associated with mortality (HR 0.102, 95% CI 0.013-0.826; P = 0.032) in univariate analysis. Post-treatment PH was also associated with poor prognosis in multivariate analysis (HR 5.7, 95% CI 1.08-30.91; P = 0.041). PAS patients are frequently misdiagnosed with PE in Korea. Post-treatment PH is associated with a poor prognosis.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2016) conducted a cohort in Primary Pulmonary Artery Sarcoma (n=20). Post-treatment pulmonary hypertension vs. Absence of post-treatment pulmonary hypertension was evaluated on Mortality (HR 5.7, 95% CI 1.08-30.91, p=0.041). Post-treatment pulmonary hypertension was associated with increased mortality in patients with primary pulmonary artery sarcoma.
Synapse has enriched 10 related papers. Consider them for comparative context: